Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner

Key Takeaways Epidiolex drives a quarter of Jazz's revenues and topped $772M in sales in the first nine months of 2025.Growth stems from expanding global launches, rising adoption and momentum toward blockbuster status.Jazz's oncology and neuroscience drugs add diversified revenues as pipeline setbacks weigh on progress.Though JAZZ Pharmaceuticals (JAZZ) is not your typical marijuana stock, it is an unconventional player in this field.The company entered the cannabis space after acquiring GW Pharmaceuticals ...